单克隆丙种球蛋白病相关肌病的临床病理特征、发病机制与治疗
本文综述了单克隆丙种球蛋白病相关肌病(MGAM)的四种亚型:AL淀粉样肌病、散发性晚发线状体肌病(SLONM)、伴肌病的硬化性黏液水肿及新报道的MGGSM。各亚型多见于40岁以上,常亚急性起病,表现为快速进展的近端和轴性肌无力,伴吞咽困难和体重下降。肌肉活检是唯一诊断方法,治疗包括针对浆细胞克隆的化疗或免疫调节。
要点
- MGAM四种亚型均多见于40岁以上,亚急性起病,近端和轴性肌无力快速进展。
- AL淀粉样肌病和SLONM常见血清CK正常,硬化性黏液水肿相关肌病和MGGSM常伴高CK血症。
- 肌肉活检是唯一诊断方法,需包括改良Gömöri三色、刚果红、PAS、阿尔新蓝及α-actinin免疫组化染色。
核心结论
- MGAM是罕见但可治疗的肌病,早期识别和针对性治疗可改善预后。
- AL淀粉样肌病和部分SLONM需针对浆细胞克隆的治疗,其他亚型可能受益于免疫调节治疗。
研究设计与样本
- 本文为综述,总结单克隆丙种球蛋白病相关肌病的临床病理特征、发病机制和治疗。
主要发现
- MGAM四种亚型包括AL淀粉样肌病、SLONM、伴肌病的硬化性黏液水肿和新报道的MGGSM。
- 各亚型多见于40岁以上患者,常亚急性起病,表现为快速进展的近端和轴性肌无力。
- 吞咽困难和体重下降常见,周围神经病在AL淀粉样肌病中频繁出现,其他亚型一般无。
- 血清CK水平因亚型而异:AL淀粉样肌病和SLONM常正常,硬化性黏液水肿相关肌病和MGGSM常升高。
- 肌肉活检是唯一诊断方法,需结合组织化学和免疫组化染色识别各亚型病理特征。
关键数值与推荐
- 肌肉活检应包含改良Gömöri三色、刚果红、过碘酸-雪夫(PAS)、阿尔新蓝染色及α-actinin免疫组化。
- AL淀粉样肌病和部分SLONM应尽早行针对浆细胞克隆的治疗,如自体干细胞移植或全身化疗。
- 硬化性黏液水肿相关肌病、MGGSM和SLONM可考虑免疫调节治疗。
临床怎么用
- 对40岁以上亚急性起病的近端和轴性肌无力患者,应警惕MGAM并筛查单克隆丙种球蛋白。
- 疑诊MGAM时应行肌肉活检,并包含上述组织化学和免疫组化染色以明确亚型。
- 确诊后根据亚型选择浆细胞定向治疗或免疫调节治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Monoclonal gammopathy-associated myopathies (MGAMs) are rare yet treatable myopathies that occur in association with monoclonal gammopathies. These myopathies include light chain (AL) amyloidosis myopathy, sporadic late-onset nemaline myopathy (SLONM), scleromyxedema with associated myopathy, and newly reported monoclonal gammopathy-associated glycogen storage myopathy (MGGSM), including the vacuolar myopathy with monoclonal gammopathy and stiffness. All these 4 distinct subtypes of MGAMs typically present in patients aged 40 or older, frequently with a subacute onset of rapidly progressive proximal and axial muscle weakness. Dysphagia and weight loss are often present. Peripheral neuropathy is frequent in AL amyloidosis but is generally absent in other MGAM subtypes unless there is a concurrent paraproteinemic neuropathy. Serum creatine kinase (CK) levels vary across MGAM subtypes. AL amyloidosis myopathy and SLONM are often associated with normal CK levels, whereas scleromyxedema-associated myopathy and MGGSM are often accompanied by hyperCKemia. Muscle biopsy remains the only diagnostic test for MGAMs. Histochemical stains, such as modified Gömöri trichrome, Congo red, periodic acid-Schiff, and Alcian blue, and immunohistochemical stain with α-actinin should be included in the evaluation of patients with suspected MGAMs to identify the pathologic features specific to each MGAM subtype. Although the pathogenesis of MGAMs is not well understood, an underlying immune-mediated mechanism likely contributes to most subtypes, except in AL amyloidosis myopathy, where tissue amyloid deposition and direct light chain toxicity are believed to play a central role. Prompt plasma cell-directed therapy aimed at eliminating the culprit plasma cell clone, such as autologous stem cell transplantation or systemic chemotherapy, is warranted to improve clinical outcomes in AL amyloidosis myopathy and in some patients with SLONM, whereas immunomodulatory therapy may be beneficial in patients with scleromyxedema-associated myopathy, MGGSM, and SLONM.
引用
- Soontrapa P, Jones FJS, Milone M, et al. Clinicopathologic Features, Pathogenesis, and Treatment of Monoclonal Gammopathy-Associated Myopathies. Neurology. 2025. PMID: 40921022. doi:10.1212/WNL.0000000000214101
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。